VEGFA and neoplasm: Undeniably, high plasma VEGF is associated with worse outcomes regardless of bevacizumab therapy, being a prognostic marker rather than a predictive one [96]; nevertheless, while thinking about post-transcription regulation of VEGF, short isoforms (VEGF110,120) can easily diffuse in the tumor site.